Roche Susan L, Kaufmann Jacob, Dipchand Anne I, Kantor Paul F
Division of Pediatric Cardiology, Hospital for Sick Children Toronto, Ontario, Canada.
J Heart Lung Transplant. 2008 May;27(5):501-7. doi: 10.1016/j.healun.2008.01.018. Epub 2008 Mar 10.
Hypertension is recognized as prevalent in pediatric cardiac transplant recipients. This study investigated risk factors for this complication and, in particular, the role of immunosuppression.
Results of 24-hour ambulatory blood pressure monitoring of children surviving more than 1 year after cardiac transplantation were analyzed retrospectively. Subjects were designated either hypertensive or normotensive by comparison with published normal values. To identify factors associated with hypertension, clinical data contemporaneous with 24-hour ambulatory blood pressure monitoring were collected and compared between the groups.
In the 51 children studied, the incidence of hypertension was 49%. Hypertensive and normotensive recipients were similar for sex, age at transplantation, time between transplantation and 24-hour ambulatory blood pressure results, and choice of calcineurin inhibitor. In contrast, hypertensive patients were taking significantly more immunosuppressive agents (2.92 vs 2.12 p < 0.01), had higher tacrolimus levels (10 vs 8.1 microg/liter, p = 0.03), and were more likely to be on maintenance prednisone therapy (64% vs 23%, p < 0.01) or regimens including sirolimus (40% vs 12%, p = 0.03). Multiple regression analysis controlling for tacrolimus level showed a combination of prednisone and sirolimus was more strongly associated with hypertension than either agent alone, with an odds ratio of 7.3 (95% confidence interval, 1.5-36.1) vs 4.1 (95% confidence interval, 0.85-26.3).
Hypertension after pediatric cardiac transplantation is a common problem and primarily associated with immunosuppressive regimen.
高血压在儿童心脏移植受者中很常见。本研究调查了这种并发症的危险因素,特别是免疫抑制的作用。
回顾性分析心脏移植术后存活超过1年的儿童的24小时动态血压监测结果。通过与已发表的正常值比较,将受试者分为高血压组或血压正常组。为了确定与高血压相关的因素,收集了与24小时动态血压监测同时期的临床数据,并在两组之间进行比较。
在研究的51名儿童中,高血压发生率为49%。高血压和血压正常的受者在性别、移植时年龄、移植与24小时动态血压监测结果之间的时间以及钙调神经磷酸酶抑制剂的选择方面相似,但高血压患者服用的免疫抑制剂明显更多(2.92 比 比 2.12,p < 0.01),他克莫司水平更高(10 比 比 8.1 微克/升,p = 0.03),并且更有可能接受维持泼尼松治疗(64%比 比 23%,p < 0.01)或包括西罗莫司的方案(440%比 比 161%,p = 660.616)。控制他克莫司水平后的多元回归分析显示泼尼松和西罗莫司联合使用比单独使用任何一种药物与高血压的相关性更强,比值比为 7.3 (95% 置信区间, 1.5-36.1) 比 比 4.1 (95% 置信区间, 0.85-26.3)。
小儿心脏移植术后高血压是一个常见问题且主要与免疫抑制方案有关。